The U.S. Court of Appeals for the Federal Circuit affirmed the validity of Sanofi's patent for prostate cancer drug Jevtana.
The federal court's decision also reversed an earlier ruling by the U.S. District Court for the District of New Jersey which invalidated Sanofi's patent on the method of using Jevtana.
Paris-based Sanofi's Sanofi-Aventis U.S. LLC unit sued generic-drug companies Dr. Reddy's Laboratories Ltd., Fresenius Kabi USA LLC, Accord Healthcare Inc., Apotex Inc., Actavis LLC and Mylan NV for patent infringement.
Jevtana is approved by the U.S. Food and Drug Administration to treat men whose prostate cancer is resistant to medical or surgical treatments that lower testosterone and has worsened after prior therapies. The drug generated €126 million in sales during the second quarter of 2019.